E company news, Changchun High-tech (000661) announced on the evening of February 5 that recently, the company's subsidiary Jinsai Pharmaceutical received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, and the application for clinical trial registration of GenSci120 injection for domestic production of Jinsai Pharmaceutical was approved. Indications for this drug include inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).

More related articlesShenlian Bio's wholly-owned subsidiary intends to subscribe to the new registered capital of Shizhiyuan and will hold 20... Shenlian Biotechnology (688098) announced on the evening of February 5 that the company intends to increase or borrow from its wholly-owned subsidiary, Shanghai Ben Tiancheng Biopharmaceutical Co., Ltd. (hereinafter referred to as "Ben Tiancheng"), and Ben Tiancheng will subscribe to the new registered capital of Shizhiyuan of RMB 37.3391 million with 60 million yuan, accounting for the future generations of this transaction. Securities Times E Company Sun Xianchao 02-05 18:54At the end of 2024, Yongji Co., Ltd. (603058) held the fifth meeting of the sixth board of directors to deliberate and pass the "Proposal on the Proposed Foreign Investment and Signing of the Agreement of Intent of Wholly-owned Subsidiaries", and the company's second-level wholly-owned subsidiary, Y Cannabis Holdings Pty Ltd (hereinafter referred to as the "... Securities Times E Company Zhao Liyun 02-05 18:53